France & Gilead Sciences
4 shared events · Importance 4 · Last updated Jul 31, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
International
France: One of the Western countries that slashed foreign assistance, contributing to Joint United Nations Programme on HIV/AIDS funding loss.
Gilead Sciences: Developed lenacapavir, a highly effective HIV prevention injectable; faces potential revenue impact from generic production in South Africa.
Jul 21, 2026 · 6 articles
International
France: Reduced HIV funding as part of European cuts, contributing to the overall decline.
Gilead Sciences: Facing pressure to expand access to lenacapavir; its pricing and licensing decisions are under scrutiny.
Jul 21, 2026 · 68 articles
Accidents
France: Confirmed one case in a doctor who recovered; no further spread.
Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.
Mar 09, 2018 · 314 articles
Accidents
France: Reported first case outside Africa in a humanitarian worker who recovered.
Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.
Jul 06, 2026 · 410 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how France and Gilead Sciences interact across events, view sentiment trends, and discover connected entities.
Open Dashboard